Gregory Wesner is the founder of Receptor Life Sciences. Receptor Life Sciences has raised $29M in total funding. Latest round: Series A.
Gregory Wesner is the CEO of Receptor Life Sciences, a Seattle-based biotech company focused on developing cannabinoid medicines delivered via an inhaler. The company raised $29 million in its Series A funding round to advance its products through the investigational new drug process. Wesner previously served as the chair of intellectual property litigation for the Seattle law firm Lane Powell.
Full founder directory · Investor directory · Company funding database · Fundraising library